Antivirals in the management of an influenza pandemic
Mary Ellen Harrod1, Sean Emery, Dominic E Dwyer
1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia. mharrod@nchecr.unsw.edu.au
Abstract:
The Australian Government has an extensive stockpile of antivirals (neuraminidase inhibitors) to be used if an influenza pandemic occurs. Neuraminidase inhibitors reduce the duration of the symptoms of seasonal influenza infection by 1 day on average, when used as treatment within 48 hours of disease onset. Neuraminidase inhibitors prevent infection in up to 74% of people when administered as prophylaxis. Resistance of seasonal influenza viruses to neuraminidase inhibitors is low. The safety and efficacy (including resistance) of neuraminidase inhibitors against pandemic influenza or the virus of current concern in pandemic planning, influenza A/H5N1, is not known, and further research is needed.
More Related Videos
Related Concept Videos
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Influenza
Antiviral Nucleoside Inhibitors
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Inhibitors of Virion Maturation and Assembly


